Core--Cellular therapy

核心--细胞治疗

• 批准号: 6728867
• 负责人: Shelly Heimfeld
• 金额: $ 7.78万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-03-12 至 2007-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6728867
• 关键词: animal tissue; biomedical facility; blood treatment; cell population study; cell transplantation; flow cytometry; human tissue; tissue /cell culture; transplantation immunology

The Cellular Therapy Shared Resource is an integral part of the Consortium and plays a critical role in the Clinical Transplantation program. Cellular Therapy helps support research by providing four specific functions. First, the resource provides the critical instrumentation and technical expertise in apheresis collection, cell processing, cryopreservation, and the infusion of cells. Included within this objective are the development of new cell selection and culturing techniques in support of novel autologous and allogeneic treatment protocols. Second, Cellular Therapy provides large-scale processing capabilities in support of specific research studies involving human, primate, and canine cells. This again encompasses the development of novel cell selection approaches and the preclinical validation of such research procedures for implementation in clinical studies. Third, the laboratory performs quantitative flow cytometry analyses and in vitro colony forming assays on various cellular components utilized for both clinical and research studies. These data are useful in determining which specific cell populations may be correlated with specific clinical outcomes. This in turn helps to stimulate the development of novel graft engineering approaches and techniques that could improve future transplantation studies. Fourth, Cellular Therapy procures and provides both patient and normal donor specimens in support of research projects. These samples, obtained under IRB approved protocols from fresh specimens and from an already established Repository Specimens for Research Studies, will be extremely useful in helping Center investigators to define the mechanisms involved in engraftment, disease control, immune reconstitution, and graft-versus-host disease. This application requests continued support for a resource which fulfills an essential role for peer reviewed research.

细胞治疗共享资源是联盟的一个组成部分，在临床移植计划中发挥着关键作用。细胞疗法通过提供四种特定功能来帮助支持研究。首先，该资源提供了关键的仪器和技术专业知识，在单采采集，细胞处理，冷冻保存和细胞输注。这一目标包括开发新的细胞选择和培养技术，以支持新的自体和同种异体治疗方案。其次，细胞治疗提供大规模的处理能力，以支持涉及人类，灵长类动物和犬细胞的特定研究。这再次包括开发新的细胞选择方法和临床前验证这些研究程序，以在临床研究中实施。第三，实验室对用于临床和研究的各种细胞成分进行定量流式细胞术分析和体外集落形成试验。这些数据有助于确定哪些特定细胞群可能与特定临床结果相关。这反过来又有助于刺激新的移植工程方法和技术的发展，可以改善未来的移植研究。第四，细胞治疗采购和提供患者和正常供体标本，以支持研究项目。这些样品， IRB批准了来自新鲜标本和已建立的储存库的方案 用于研究的标本，将非常有助于中心研究人员确定植入、疾病控制、免疫重建和移植物抗宿主病的机制。此应用程序要求持续支持的资源，履行同行评审研究的重要作用。